Transporter
Dopamine transporter
Sodium-dependent dopamine transporter
- GeneSLC6A3
- FamilyMonoamine transporters
- GroupMonoamine transporters
The dopamine transporter carries dopamine into the cell, driven by sodium. The human transporter was cloned from the substantia nigra, its gene lies on chromosome 5, and cocaine and amphetamine block its uptake of dopamine.1 In rat brain, antibodies showed the transporter in the cell bodies and in the terminal fields of the dopamine neurons of the midbrain. It was densest in the dorsal and ventral striatum, the nucleus accumbens and the olfactory tubercle, and less concentrated in the globus pallidus, the entopeduncular nucleus and the medial forebrain bundle. In the striatum it was enriched in patches. The noradrenergic locus coeruleus and the serotonergic raphe nuclei showed no labelling, and destroying the dopamine pathway on one side abolished the labelling in the striatum and cingulate cortex.2 Where the transporter is scarce, other transporters clear dopamine. In the frontal cortex of mice, dopamine uptake into nerve terminals was blocked by cocaine and by nisoxetine, an inhibitor of the noradrenaline transporter, but not by the DAT inhibitor GBR12909. In the caudate and the nucleus accumbens, uptake depends mainly on the dopamine transporter. Which transporter clears dopamine in a region depends on both the affinities and the local densities of the transporters.3
In rats, the potency of cocaine-like drugs in self-administration followed their binding to the dopamine transporter, and not their binding to a large number of other sites in the brain.4 In experienced cocaine users, at least 47 percent of the transporters had to be blocked before users perceived the effects of cocaine.5
A review of addictive drugs names three main factors that drive striatal dopamine, namely neuronal firing, reuptake through this transporter and the state of the presynaptic terminal. Cocaine acts by inhibiting reuptake, other drugs act by enhancing firing or by changing release from the terminal. The common principle is that each drug raises synaptic dopamine in a way that is detached from the normal drive by environmental cues.6
Mice without the transporter are hyperactive, dopamine stays outside their cells at least 100 times longer, and cocaine and amphetamine no longer change their activity.7 These mice are a genetic model of persistent functional hyperdopaminergia. Without the transporter no other mechanism keeps the extracellular dopamine in check, and the levels of the postsynaptic D1 and D2 receptors are downregulated.8 Amphetamine needs the transporter to release dopamine. In mice lacking it, amphetamine no longer raised dopamine outside the cells, while in normal mice it rose about tenfold.9 Amphetamine also acts at the vesicles. In cultured midbrain dopamine neurons it rapidly reduced the pH gradient across the vesicle membrane, and in isolated chromaffin granules this reduced the uptake and increased the release of transmitter. A later review describes how amphetamines combine several effects to release dopamine by reverse transport, independent of exocytosis and of normal firing.10,6
In a PET study of ten healthy men, modafinil at doses used in treatment blocked dopamine transporters and raised dopamine in the brain, also in the nucleus accumbens.11
The transporter also takes up toxins. MPP+, the active metabolite of the neurotoxin MPTP, is carried into dopamine neurons by the transporter, and MPTP causes a parkinsonian syndrome in humans and animals. A direct interaction between the transporter and the protein alpha-synuclein, which is implicated in Parkinson's disease, increased the transporter activity in cells and with it the toxicity of MPP+.8
Sources (11)
- Giros et al. 1992Giros B, el Mestikawy S, Godinot N, et al. (1992) Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter Mol Pharmacol
- Ciliax et al. 1995Ciliax BJ, Heilman C, Demchyshyn LL, et al. (1995) The dopamine transporter: immunochemical characterization and localization in brain J Neurosci
- Morón et al. 2002Morón JA, Brockington A, Wise RA, et al. (2002) Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines J Neurosci
- Ritz et al. 1987Ritz MC, Lamb RJ, Goldberg SR, et al. (1987) Cocaine receptors on dopamine transporters are related to self-administration of cocaine Science
- Volkow et al. 1997Volkow ND, Wang GJ, Fischman MW, et al. (1997) Relationship between subjective effects of cocaine and dopamine transporter occupancy Nature
- Sulzer 2011Sulzer D (2011) How Addictive Drugs Disrupt Presynaptic Dopamine Neurotransmission Neuron
- Giros et al. 1996Giros B, Jaber M, Jones SR, et al. (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter Nature
- Torres et al. 2003Torres GE, Gainetdinov RR, Caron MG (2003) Plasma membrane monoamine transporters: structure, regulation and function Nature Reviews Neuroscience
- Jones et al. 1998Jones SR, Gainetdinov RR, Wightman RM, et al. (1998) Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter J Neurosci
- Sulzer et al. 1990Sulzer D, Rayport S (1990) Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action Neuron
- Volkow et al. 2009Volkow ND, Fowler JS, Logan J, et al. (2009) Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications JAMA
Binding affinity (Kᵢ)
21 substances, 32 displayed values. Strongest first within each organism. The bar is pKᵢ on a log scale. Open a row to see the assay and every report behind the value.
Human
18 measurements
α-PVP7.0 nMRickli et al. 2015
- Assay
- cloned DAT receptor or transporter binding (HEK293 cell membranes)
- Shown value from
- Rickli et al. 2015, Table 2
- Error
- ± 2.0 SD
MDPV19 nMEshleman et al. 2013 · 2 reports
- Assay
- HEK-293 cells expressing human DAT, [125I]RTI-55 displacement
- Shown value from
- Eshleman et al. 2013, Table 2
- Range
- 10–19 nM in 2 reports
- Error
- ± 3.2 SEM, n = 3
Sources and values behind the range, same assay family Report Value Where Simmler et al. 2013 10 nM Table 1 Eshleman et al. 2013 19 nM Table 2 Methylphenidate60 nMHan et al. 2006
- Assay
- Uptake inhibition in Intestine 407 cells transiently expressing human DAT
- Shown value from
- Han et al. 2006, Table 1
- Error
- ± 10 SEM, n = 4
Diphenidine317 nMWallach et al. 2016
- Assay
- NIMH PDSP target-specific radioligand binding panel; secondary concentration-response assay after >50% inhibition at 10 µM
- Shown value from
- Wallach et al. 2016, Figure 2
Cocaine494 nMEshleman et al. 2017 · 10 reports
- Assay
- [125I]RTI-55 radioligand binding inhibition at human DAT in HEK293 cells
- Shown value from
- Eshleman et al. 2017, Table 1
- Range
- 164–595 nM in 10 reports
- Error
- ± 37 SEM, n = 29
This is the best-supported value. Other reports differ. 12 reports in all, 140–595 nM.
Sources and values behind the range, same assay family Report Value Where Simmler et al. 2013 280 nM Table 1 Eshleman et al. 2017 494 nM Table 1 Eshleman et al. 2018 595 nM Table 3 Janowsky et al. 2014 416 nM Table 4 Eshleman et al. 2014 462 nM Table 3 Schmitt et al. 2011 164 nM Table 1 Andersen et al. 2015 372 nM Supporting Table S3 Eshleman et al. 2013 558 nM Table 2 Carroll et al. 2009 272 nM Table 1 6-APB600 nMRickli et al. 2015
- Assay
- cloned DAT receptor or transporter binding (HEK293 cell membranes)
- Shown value from
- Rickli et al. 2015, Table 2
- Error
- ± 50 SD
Amphetamine640 nMHan et al. 2006
- Assay
- Uptake inhibition in Intestine 407 cells transiently expressing human DAT
- Shown value from
- Han et al. 2006, Table 1
- Error
- ± 140 SEM, n = 4
Values depend on the assay, species or conditions, and each is valid only for its own. 2 reports in all, 640–5680 nM.
Bupropion810 nMAndersen et al. 2015 · 5 reports
- Assay
- COS-7 membranes expressing wild-type human DAT, [125I]beta-CIT competition binding
- Shown value from
- Andersen et al. 2015, Supporting Table S3
- Range
- 320–871 nM in 5 reports
- Error
- ± 207 SEM, n = 3
Values depend on the assay, species or conditions, and each is valid only for its own. 6 reports in all, 320–1236 nM.
Sources and values behind the range, same assay family Report Value Where Schmitt et al. 2011 320 nM Table 1 Andersen et al. 2015 810 nM Supporting Table S3 Lapinsky et al. 2009 441 nM Table 1 Carroll et al. 2009 871 nM Table 1 Butylone1730 nMEshleman et al. 2013 · 2 reports
- Assay
- HEK-293 cells expressing human DAT, [125I]RTI-55 displacement
- Shown value from
- Eshleman et al. 2013, Table 2
- Range
- 440–1730 nM in 2 reports
- Error
- ± 270 SEM, n = 7
Reported values disagree and no value is established. 2 reports in all, 440–1730 nM.
Sources and values behind the range, same assay family Report Value Where Simmler et al. 2013 440 nM Table 1 Eshleman et al. 2013 1730 nM Table 2 Ibogaine1980 nMMash et al. 1995
- Assay
- human occipital cortex membranes, [125I]RTI-121 displacement
- Shown value from
- Mash et al. 1995, Results
- Error
- ± 460 SEM
Modafinil2143 nMSchmitt et al. 2011
- Assay
- intact stably transfected HEK293 cells expressing hDAT, [3H]CFT displacement
- Shown value from
- Schmitt et al. 2011, Table 1
- Error
- ± 215 SEM
5-APB2600 nMRickli et al. 2015
- Assay
- cloned DAT receptor or transporter binding (HEK293 cell membranes)
- Shown value from
- Rickli et al. 2015, Table 2
- Error
- ± 300 SD
Methoxphenidine2915 nMWallach et al. 2016
- Assay
- NIMH PDSP target-specific radioligand binding panel; secondary concentration-response assay after >50% inhibition at 10 µM
- Shown value from
- Wallach et al. 2016, Figure 2
Methamphetamine4580 nMEshleman et al. 2017 · 4 reports
- Assay
- [125I]RTI-55 radioligand binding inhibition at human DAT in HEK293 cells
- Shown value from
- Eshleman et al. 2017, Table 1
- Range
- 1850–4750 nM in 4 reports
- Error
- ± 760 SEM, n = 23
This is the best-supported value. Other reports differ. 5 reports in all, 460–4750 nM.
Sources and values behind the range, same assay family Report Value Where Simmler et al. 2013 1850 nM Table 1 Eshleman et al. 2017 4580 nM Table 1 Eshleman et al. 2014 4750 nM Table 3 Eshleman et al. 2013 3960 nM Table 2 Mephedrone4800 nMEshleman et al. 2013 · 2 reports
- Assay
- HEK-293 cells expressing human DAT, [125I]RTI-55 displacement
- Shown value from
- Eshleman et al. 2013, Table 2
- Range
- 3400–4800 nM in 2 reports
- Error
- ± 750 SEM, n = 3
Sources and values behind the range, same assay family Report Value Where Simmler et al. 2013 3400 nM Table 1 Eshleman et al. 2013 4800 nM Table 2 Methylone5020 nMEshleman et al. 2013 · 2 reports
- Assay
- HEK-293 cells expressing human DAT, [125I]RTI-55 displacement
- Shown value from
- Eshleman et al. 2013, Table 2
- Range
- 2730–5020 nM in 2 reports
- Error
- ± 290 SEM, n = 3
Sources and values behind the range, same assay family Report Value Where Simmler et al. 2013 2730 nM Table 1 Eshleman et al. 2013 5020 nM Table 2 Psilocybin6077 nMGlatfelter et al. 2022
- Assay
- Transfected-cell radioligand binding at human DAT (UNC PDSP)
- Shown value from
- Glatfelter et al. 2022, Table S1
MDMA8290 nMHan et al. 2006
- Assay
- Uptake inhibition in Intestine 407 cells transiently expressing human DAT
- Shown value from
- Han et al. 2006, Table 1
- Error
- ± 1670 SEM, n = 4
Mouse
5 measurements
Methylphenidate260 nMHan et al. 2006
- Assay
- Uptake inhibition in Intestine 407 cells transiently expressing mouse DAT
- Shown value from
- Han et al. 2006, Table 1
- Error
- ± 30 SEM, n = 4
Methamphetamine470 nMHan et al. 2006
- Assay
- Uptake inhibition in Intestine 407 cells transiently expressing mouse DAT
- Shown value from
- Han et al. 2006, Table 1
- Error
- ± 80 SEM, n = 4
Cocaine490 nMHan et al. 2006
- Assay
- Uptake inhibition in Intestine 407 cells transiently expressing mouse DAT
- Shown value from
- Han et al. 2006, Table 1
- Error
- ± 40 SEM, n = 4
Amphetamine560 nMHan et al. 2006
- Assay
- Uptake inhibition in Intestine 407 cells transiently expressing mouse DAT
- Shown value from
- Han et al. 2006, Table 1
- Error
- ± 110 SEM, n = 4
MDMA4870 nMHan et al. 2006
- Assay
- Uptake inhibition in Intestine 407 cells transiently expressing mouse DAT
- Shown value from
- Han et al. 2006, Table 1
- Error
- ± 650 SEM, n = 4
Rat
5 measurements
Methylphenidate75 nMKim et al. 2007
- Assay
- rat striatal membranes, [3H]WIN 35,428 displacement
- Shown value from
- Kim et al. 2007, Table 1
- Error
- ± 7.4 SEM
Methamphetamine114 nMRothman et al. 2001
- Assay
- Rat caudate synaptosomes, [3H]dopamine uptake inhibition, 15 min at 25 °C
- Shown value from
- Rothman et al. 2001, Table V
- Error
- ± 11 SD, n = 3
Cocaine156 nMKim et al. 2007
- Assay
- rat striatal membranes, [3H]WIN 35,428 displacement
- Shown value from
- Kim et al. 2007, Table 1
- Error
- ± 11 SEM
MDMA1572 nMRothman et al. 2001
- Assay
- Rat caudate synaptosomes, [3H]dopamine uptake inhibition, 15 min at 25 °C
- Shown value from
- Rothman et al. 2001, Table V
- Error
- ± 59 SD, n = 3
Ephedrine4398 nMRothman et al. 2001
- Assay
- Rat caudate synaptosomes, [3H]dopamine uptake inhibition, 15 min at 25 °C
- Shown value from
- Rothman et al. 2001, Table V
- Error
- ± 213 SD, n = 3
Unspecified
4 measurements
Methylphenidate110 nMFroimowitz et al. 2007
- Assay
- [125I]RTI-55 binding at the DAT
- Shown value from
- Froimowitz et al. 2007, Table 1
- Error
- ± 9.0 SEM
Ephenidine379 nMKang et al. 2017
- Assay
- NIMH PDSP radioligand binding, [3H]WIN35428 (0.5 nM), species not stated
- Shown value from
- Kang et al. 2017, Results (NIMH PDSP secondary assay, Table 1 not in the supplied PDF)
Cocaine500 nMFroimowitz et al. 2007
- Assay
- [125I]RTI-55 binding at the DAT
- Shown value from
- Froimowitz et al. 2007, Table 1
- Error
- ± 65 SEM
3-MeO-PCE743 nMRoth BryanL et al. 2018
- Assay
- NIMH PDSP radioligand binding, DAT
- Shown value from
- Roth BryanL et al. 2018, Corrected Supplementary Table S1
Functional potency (EC₅₀)
13 substances, 18 displayed values. Strongest first within each organism. Emax is shown where the paper reports it. Efficacy depends on the assay and its reference agonist.
Human
5 measurements
Methamphetamine435 nMEshleman et al. 2017 · 4 reports
- Assay
- Release of preloaded [3H]neurotransmitter from HEK293 cells expressing human DAT
- Shown value from
- Eshleman et al. 2017, Table 3
- Range
- 400–1560 nM in 4 reports
- Error
- ± 74 SEM, n = 13
- Emax
- 101.3 ± 2.9%
This is the best-supported value. Other reports differ. 4 reports in all, 400–1560 nM.
Sources and values behind the range, same assay family Report Value Where Simmler et al. 2013 1560 nM Table 3 Eshleman et al. 2017 435 nM Table 3 Eshleman et al. 2014 970 nM Table 3 Eshleman et al. 2013 400 nM Table 3 Mephedrone1190 nMEshleman et al. 2013 · 2 reports
- Assay
- HEK-293 cells expressing human DAT, release of preloaded [3H]dopamine
- Shown value from
- Eshleman et al. 2013, Table 3
- Range
- 1190–3750 nM in 2 reports
- Error
- ± 340 SEM, n = 5
- Emax
- 68.0 ± 11.0%
Reported values disagree and no value is established. 2 reports in all, 1190–3750 nM.
Sources and values behind the range, same assay family Report Value Where Simmler et al. 2013 3750 nM Table 3 Eshleman et al. 2013 1190 nM Table 3 Amphetamine1760 nMSimmler et al. 2013
- Assay
- Monoamine release from preloaded HEK293 cells overexpressing human DAT
- Shown value from
- Simmler et al. 2013, Table 3
Cathinone5640 nMSimmler et al. 2013
- Assay
- Monoamine release from preloaded HEK293 cells overexpressing human DAT
- Shown value from
- Simmler et al. 2013, Table 3
MDMA7500 nMEshleman et al. 2017 · 2 reports
- Assay
- Release of preloaded [3H]neurotransmitter from HEK293 cells expressing human DAT
- Shown value from
- Eshleman et al. 2017, Table 3
- Range
- 4800–7500 nM in 2 reports
- Error
- ± 2300 SEM, n = 10
- Emax
- 94.0 ± 10.0%
Sources and values behind the range, same assay family Report Value Where Eshleman et al. 2017 7500 nM Table 3 Eshleman et al. 2013 4800 nM Table 3
Rat
13 measurements
6-APB10 nMBrandt et al. 2020
- Assay
- Transporter-mediated monoamine release in rat brain synaptosomes
- Shown value from
- Brandt et al. 2020, Table 1
- Error
- ± 1.0 SD, n = 3
- Emax
- 101.0%
Amphetamine13 nMFitzgerald et al. 2024 · 2 reports
- Assay
- Monoamine release in rat brain synaptosomes
- Shown value from
- Fitzgerald et al. 2024, Table 1
- Range
- 13–25 nM in 2 reports
Sources and values behind the range, same assay family Report Value Where Fitzgerald et al. 2024 13 nM Table 1 Rothman et al. 2003 25 nM Table 1 Cathinone19 nMRothman et al. 2003 · 3 reports
- Assay
- rat brain synaptosomes, release of [3H]MPP+
- Shown value from
- Rothman et al. 2003, Table 1
- Range
- 19–83 nM in 3 reports
- Error
- ± 0.30 SD, n = 3
Sources and values behind the range, same assay family Report Value Where Fitzgerald et al. 2024 35 nM Table 1 Rothman et al. 2003 19 nM Table 1 Blough et al. 2019 83 nM Table 1 Methamphetamine28 nMNagai et al. 2007 · 4 reports
- Assay
- rat brain synaptosome monoamine release
- Shown value from
- Nagai et al. 2007, Table 3
- Range
- 8.5–28 nM in 4 reports
- Error
- ± 6.5 SD, n = 3
Sources and values behind the range, same assay family Report Value Where Fitzgerald et al. 2024 11 nM Table 1 Nagai et al. 2007 28 nM Table 3 Rothman et al. 2003 25 nM Table 1 Baumann et al. 2012 8.5 nM Table 1 5-APB31 nMBrandt et al. 2020
- Assay
- Transporter-mediated monoamine release in rat brain synaptosomes
- Shown value from
- Brandt et al. 2020, Table 1
- Error
- ± 3.0 SD, n = 3
- Emax
- 103.0%
5-MAPB41 nMBrandt et al. 2020
- Assay
- Transporter-mediated monoamine release in rat brain synaptosomes
- Shown value from
- Brandt et al. 2020, Table 1
- Error
- ± 3.0 SD, n = 3
- Emax
- 103.0%
Mephedrone103 nMChojnacki et al. 2023 · 3 reports
- Assay
- rat caudate synaptosomes, release of preloaded [3H]MPP+
- Shown value from
- Chojnacki et al. 2023, Table 1
- Range
- 49–103 nM in 3 reports
- Error
- ± 16 SD, n = 3
- Emax
- 114.0%
Sources and values behind the range, same assay family Report Value Where Walther et al. 2019 49 nM Table 1 (4-Me row) Chojnacki et al. 2023 103 nM Table 1 Baumann et al. 2012 49 nM Table 1 MDA106 nMBrandt et al. 2020
- Assay
- Transporter-mediated monoamine release in rat brain synaptosomes
- Shown value from
- Brandt et al. 2020, Table 1
- Error
- ± 7.0 SD, n = 3
- Emax
- 104.0%
MDMA120 nMBrandt et al. 2020 · 3 reports
- Assay
- Transporter-mediated monoamine release in rat brain synaptosomes
- Shown value from
- Brandt et al. 2020, Table 1
- Range
- 51–200 nM in 3 reports
- Error
- ± 8.0 SD, n = 3
- Emax
- 101.0%
Sources and values behind the range, same assay family Report Value Where Brandt et al. 2020 120 nM Table 1 Nagai et al. 2007 200 nM Table 3 Baumann et al. 2012 51 nM Table 1 4-FA200 nMNagai et al. 2007
- Assay
- rat brain synaptosome monoamine release
- Shown value from
- Nagai et al. 2007, Table 3
- Error
- ± 48 SD, n = 3
Methylone220 nMGlatfelter et al. 2021 · 3 reports
- Assay
- rat brain synaptosomes, release of [3H]dopamine
- Shown value from
- Glatfelter et al. 2021, Table 1
- Range
- 133–380 nM in 3 reports
- Error
- ± 40 SD, n = 3
- Emax
- 102.0%
Sources and values behind the range, same assay family Report Value Where Nagai et al. 2007 380 nM Table 3 Glatfelter et al. 2021 220 nM Table 1 Baumann et al. 2012 133 nM Table 1 Ephedrine236 nMRothman et al. 2003
- Assay
- rat brain synaptosomes, release of [3H]MPP+
- Shown value from
- Rothman et al. 2003, Table 1
- Error
- ± 9.0 SD, n = 3
Pseudoephedrine1988 nMRothman et al. 2003
- Assay
- rat brain synaptosomes, release of [3H]MPP+
- Shown value from
- Rothman et al. 2003, Table 1
- Error
- ± 50 SD, n = 3
Also reported to act here
Substances reported to act here, without a displayed value.
Values are published numbers in nM per organism. Different assays, species and receptor preparations are not directly interchangeable, and a value does not establish clinical potency or safety.